Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder

• Status: Completed
• Trial end date: 2007-06-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the efficacy and safety of quetiapine fumarate sustained release (Seroquel SR) in the treatment of Major Depressive Disorder.

PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Citalopram; Quetiapine Fumarate

Criteria

Inclusion Criteria:

• Male or female aged 18 to 65 years

• A documented diagnosis of major depressive disorder

Exclusion Criteria:

• Patients with a DSM IV Axis I disorder other than MDD within 6 months of enrolment

• Patients with a diagnosis of DSM IV Axis II disorder which has a major impact on the patient's current psychiatric status

• Patients whose current episode of depression exceeds 12 months or is less than 4 weeks prior to enrolment